Drugs / GP350 CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07306156 | Nov 2025 → Nov 2030 expected | Epstein-Barr virus-associated lymphoproliferative disorder | Zhimin Zhai | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP350 CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07306156 ↗ |
| Modality | Cell therapy | “an intravenous infusion of CAR-T cells” NCT07306156 ↗ |
| Route | Intravenous | “administered via intravenous injection” NCT07306156 ↗ |